Patient Survival With and Without Radiation Therapy for Early-Stage Diffuse Large B-Cell Lymphoma in the Era of PET and Rituximab

McLaughlin, Christopher; Ricco, Anthony; Singh, Raj; Mukhopadhyay, Nitai D.; Skoro, Nevena; Girma, Selamawit; Deng, Xiaoyan; Song, Shiyu

doi:10.1016/j.adro.2022.100930

Cited by 1 publication

(1 citation statement)

References 22 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following three cycles of R-CHOP, the patient’s PET/CT imaging demonstrated no evidence of persistent or recurrent disease. A retrospective study by McLaughlin et al demonstrated a survival benefit with the use of consolidation RT for early-stage DLBCL, which prompted adjuvant RT following the utilization of R-CHOP [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

A Rare Presentation of Collision Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma Treated with R-CHOP and Adjuvant Radiation Therapy

Mazraani,

Nasser,

Loving

et al. 2024

Cureus

View full text Add to dashboard Cite

Collision tumors are rare neoplasms displaying two distinct cell populations developing in juxtaposition to one another without areas of intermingling. There are currently no guidelines for the recommended treatment for such rare collision cases. We herein report a unique case of a 45-year-old female who presented with a left-sided palpable inguinal lymph node. A subsequent excisional biopsy yielded a diagnosis of collision lymphoma (CL) of nodular sclerosing Hodgkin lymphoma (HL) and germinal center diffuse large B-cell lymphoma (DLBCL). This case report highlights the challenges in managing CL and the potential efficacy of cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab regimen (R-CHOP) and adjuvant radiation therapy (RT) in treating this rare condition. Our goal is to enrich the literature with our case on CL in an attempt to progress to a path of ultimately establishing a definitive treatment approach to CL of DLBCL and HL.

show abstract

Section: Discussionmentioning

confidence: 99%